Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a steroid drop take the sting out of eye injections?

NCT ID NCT05542381

Symptom relief Sponsor: Virginia Polytechnic Institute and State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a steroid eye drop (loteprednol) can reduce pain after intravitreal injections for age-related macular degeneration. 64 participants received either the steroid drop or artificial tears right after their injection. Pain was tracked by phone over a week. The goal is to find a simple way to improve comfort after these common eye procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Loteprednol etabonate ophthalmic gel (corticosteroid eye drop)
What this could lead to
If it works, this could give doctors a simple way to reduce pain after routine eye injections for macular degeneration.
What could go wrong
This is a small, completed study (64 people) comparing the steroid to artificial tears. The results may not apply to everyone, and steroids can raise eye pressure in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

64 people

The number who actually took part.

Started

Dec 2022

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients must have age-related macular degeneration and be undergoing intravitreal injections for treatment as defined by a retina specialist. Exclusion Criteria: * Dementia * Report baseline eye pain * Use topical NSAIDs or steroids * Patient under 18 years old * History of corticosteroid responsive elevation in intraocular pressure * Allergy to Loteprednol or Nepafenac * Pre-existing chronic pain disorders * Advanced Glaucoma * Herpes zoster * Allergy to local anesthetic or penicillin * Patients unable to consent on own behalf * Patients unable to communicate pain * Pregnancy * Incarceration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration eye disorder macular degeneration retinal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration

Contacts and locations

Locations

  • Vistar Eye Center

    Roanoke, Virginia, 24019, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.